about
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerLong-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study GroupPhase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationThe bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorResponsiveness of CPT-11 in respect to hMLH1 and hMSH2 protein expression in the primary colorectal cancer.Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptorRandomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancerAll-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARĪ±-mediated DNA damagePhase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.Topotecan, an active new antineoplastic agent: review and current status.CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.Experience with irinotecan for the treatment of malignant gliomaPoly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery.A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.Topoisomerase I inhibitors and drug resistanceNew drugs in the treatment of colorectal carcinoma.CPT-11. The European experience.Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.Topoisomerase-I inhibitors in the management of colon cancer.Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.Effects of herbal supplements on the bioactivation of chemotherapeutic agents.Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs.The effects of topotecan on lipid peroxidation and antioxidant enzyme levels in rabbit liver tissue.The effect of a single injection of irinotecan on the development of enamel in the Wistar rats.In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.Ruthenium(II) polypyridyl complexes as dual inhibitors of telomerase and topoisomerase.Clinical pharmacology of camptothecins.
P2860
Q24795149-6285C65C-8CFC-44DC-AB33-68C410366D20Q30412709-619630D5-6001-4775-AB5E-5A3FC4BDDA0CQ33344289-7AEA9400-9723-45A9-B9BF-C9B6BDE79DCFQ33349102-4F1ECB4D-9AE5-474F-8179-12D0E3294C14Q33407183-003D5737-C465-4EA0-9C79-110957EE6EFDQ33495553-D8C60BF6-2FA7-43A5-AA4E-EDCFF89C1BE2Q33500497-FA132C33-4A81-46C6-A440-3ACA2CD57F4DQ33746839-5AD8D98C-4A3F-4E15-BB2B-79C82A24C6D1Q34128854-611AF20B-D8DE-4BEB-94CE-221BBC8C5FDFQ34281235-E0DC0CA9-EAA2-4070-84FD-8DD39E8622B0Q34711514-B36643A7-B1B0-4DDB-9849-8F3FD870D588Q35884399-A1AAB202-B32E-4014-A2D9-16C56015EEE6Q36027042-9E77EC26-6AEB-4477-99FE-36F16D36F276Q36074388-44DD9412-BB6A-42DB-8E2B-A8DEED4603A0Q36135270-EE57958B-D35F-4837-8617-48331825DA9EQ36179765-65D377CD-0E5A-4B94-AFF7-2C820E8E5CEAQ36617921-E46546FF-76DD-4B9D-BB36-26BB540D03A8Q37062610-526ABA58-ED92-4FD5-A2EE-2BB605AB3155Q37265907-0355D01E-918E-491B-B15A-C757CCB61084Q37415357-FD740701-41D8-4852-A310-D25276D8D898Q38074207-81899ECB-4214-4D17-BC53-C984D9D5904CQ38166233-6AADEEBA-1BFD-42E4-B505-0420F5478530Q38981028-BA9FA7F8-463E-4B25-87D8-1398E958D454Q40028536-A1E26D32-1AB5-4776-BD93-2051F80E6885Q40845274-654E78F6-A5AE-485B-88A8-04B5F3AD50E5Q40916622-8DCD7986-B52B-4486-AEF8-F1FEF146137FQ40978962-16802F0E-1C26-4B62-B76F-4573721163A1Q41308009-31D1E9C6-CD6D-4643-95DE-9788C2A2463FQ41471506-EC91C7F0-30B7-4AD0-A27E-1386319AB138Q41641046-86F35051-D38E-4E86-9A73-8D718F973285Q43762616-F05A2BEC-217C-4F05-B7FE-CA03C5F62AEEQ44444144-B92B41D8-2D75-49E5-8680-056D66108DA7Q44598660-5121F380-728F-4CCB-9BC6-F7AAE92BA56CQ46292732-2581D08C-1399-4CDD-8E64-823DC556716EQ46539384-62F57B8A-6E96-4088-9159-106364A8EAF2Q47235729-C92C70DC-D9D9-4A64-A006-21773CF815E2Q50514477-FBD930E6-BE40-4C54-B42D-0AD7C639E0EDQ52974209-56D85699-6646-484E-AF7C-62D062D8C6E4Q53780736-A082725D-A0C2-4F2D-A514-83CB259AC5DB
P2860
description
1994 nĆ® lÅ«n-bĆ»n
@nan
1994幓ć®č«ę
@ja
1994幓č«ę
@yue
1994幓č«ę
@zh-hant
1994幓č«ę
@zh-hk
1994幓č«ę
@zh-mo
1994幓č«ę
@zh-tw
1994幓č®ŗę
@wuu
1994幓č®ŗę
@zh
1994幓č®ŗę
@zh-cn
name
Topoisomerase I inhibitors: topotecan and irenotecan.
@en
type
label
Topoisomerase I inhibitors: topotecan and irenotecan.
@en
prefLabel
Topoisomerase I inhibitors: topotecan and irenotecan.
@en
P2093
P1476
Topoisomerase I inhibitors: topotecan and irenotecan.
@en
P2093
P356
10.1016/0305-7372(94)90011-6
P577
1994-01-01T00:00:00Z